Modified Orthopoxvirus Interferon-Binding Protein for Inflammation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for excessive Type I interferons, which are critical for immune responses but can cause acute inflammation and organ failure when produced in excess, lack a safe and effective method for neutralization, particularly due to species specificity and the difficulty in broadly targeting all Type I IFN subtypes.
Innovation Solution
A modified Orthopoxvirus Type I interferon-binding protein, devoid of the cell-binding region, is developed to specifically bind and neutralize Type I interferons, providing a therapeutic composition that can be administered to reduce or control harmful inflammatory responses in mammals.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If a modified Orthopoxvirus Type I interferon-binding protein is used to neutralize Type I interferons, then the harmful inflammatory effects are reduced, but the complexity of the therapeutic composition increases
Solution Approach 1:
The patent extracts and removes the cell-binding region from the Orthopoxvirus Type I interferon-binding protein, retaining only the interferon-binding domain. This extraction eliminates unnecessary complexity while preserving the neutralizing function against Type I interferons, directly resolving the contradiction between effectiveness and composition complexity.
Solution Approach 2:
The protein is segmented into functional domains, with the cell-binding region separated from the interferon-binding region. This segmentation allows the therapeutic composition to focus solely on interferon neutralization without the complicating cell-binding activity, reducing overall complexity while maintaining therapeutic efficacy.
2Ease of operation
If the cell-binding region is removed from the interferon-binding protein, then the protein can diffuse systemically and be easily cleared, but the protein's ability to bind to cells is lost
Solution Approach 1:
The cell-binding region is extracted and removed from the protein structure. This removal enables systemic diffusion and easy clearance from the body, which are desirable properties for a therapeutic agent. The loss of cell-binding function is acceptable because the therapeutic mechanism relies on interferon neutralization in circulation, not on cellular uptake.
3Reliability
If existing IFN therapies are used to treat excessive Type I interferon, then immune response is boosted, but severe and life-threatening adverse effects occur
Solution Approach 1:
The patent uses a viral-derived protein (Orthopoxvirus interferon-binding protein) that naturally binds and neutralizes interferons. By removing the cell-binding region, the harmful cell-targeting activity is eliminated while preserving the beneficial interferon-neutralizing activity. This converts a potentially harmful viral protein into a safe therapeutic agent that reduces interferon-mediated inflammation without causing severe adverse effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified protein effectively neutralizes Type I interferons, reducing inflammation and preventing negative side effects, with the ability to diffuse systemically and be easily cleared from the body, allowing for controlled regulation of IFN levels and protection against lethal shock and other inflammatory conditions.
Implementation Method 1
The compositions contain a modified Orthopoxvirus Type I interferon-binding protein (IFN-binding protein), which neutralizes Type I interferons by binding specifically thereto
Data Source
AI summary
The inventions describe here cover therapeutic compositions, and methods of use, for neutralizing Type I interferons in a mammal. The compositions contain a soluble Orthopoxvirus IFN-binding protein that is modified to remove the cell-binding region, and that specifically binds to Type I IFNs, and a pharmaceutically acceptable carrier or excipient. Another variation of the invention entails a novel IFN-binding protein that is modified to remove the cell-binding region and the signal sequence.